Nanoformulated meloxicam and rifampin: inhibiting quorum sensing and biofilm formation in Pseudomonas aeruginosa.

Nanomedicine (London, England) Pub Date : 2024-03-01 Epub Date: 2024-02-13 DOI:10.2217/nnm-2023-0268
Malihe Khorramdel, Fatemeh Peyravii Ghadikolaii, Seyed Isaac Hashemy, Hossein Javid, Masoud Homayouni Tabrizi
{"title":"Nanoformulated meloxicam and rifampin: inhibiting quorum sensing and biofilm formation in <i>Pseudomonas aeruginosa</i>.","authors":"Malihe Khorramdel, Fatemeh Peyravii Ghadikolaii, Seyed Isaac Hashemy, Hossein Javid, Masoud Homayouni Tabrizi","doi":"10.2217/nnm-2023-0268","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> We aimed to investigate the simultaneous effects of meloxicam and rifampin nanoformulations with solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) substrates on inhibiting the quorum-sensing system of <i>Pseudomonas aeruginosa</i> and preventing biofilm formation by this bacterium. <b>Methods:</b> Antimicrobial activity of rifampin and meloxicam encapsulated with SLNs and NLCs against <i>P. aeruginosa</i> PAO1 was assessed by disk diffusion, minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). <b>Results:</b> The SLN formulation was associated with lower doses for the MIC and minimum bactericidal concentration in comparison to NLC. Moreover, our results demonstrated that both nanoformulations were able to produce 100% inhibition of the biofilm formation of <i>P. aeruginosa</i> PAO1. <b>Conclusion:</b> All these findings suggest that meloxicam and rifampin encapsulated with SLNs could be the most effective formulation against <i>P. aeruginosa</i>.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nnm-2023-0268","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/13 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: We aimed to investigate the simultaneous effects of meloxicam and rifampin nanoformulations with solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) substrates on inhibiting the quorum-sensing system of Pseudomonas aeruginosa and preventing biofilm formation by this bacterium. Methods: Antimicrobial activity of rifampin and meloxicam encapsulated with SLNs and NLCs against P. aeruginosa PAO1 was assessed by disk diffusion, minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). Results: The SLN formulation was associated with lower doses for the MIC and minimum bactericidal concentration in comparison to NLC. Moreover, our results demonstrated that both nanoformulations were able to produce 100% inhibition of the biofilm formation of P. aeruginosa PAO1. Conclusion: All these findings suggest that meloxicam and rifampin encapsulated with SLNs could be the most effective formulation against P. aeruginosa.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
纳米配方美洛昔康和利福平:抑制铜绿假单胞菌的法定量感应和生物膜形成。
背景:我们旨在研究美洛昔康和利福平纳米制剂与固体脂质纳米颗粒(SLN)和纳米结构脂质载体(NLC)底物对抑制铜绿假单胞菌法定人数感应系统和防止该细菌形成生物膜的同时作用。方法通过磁盘扩散、最低抑菌浓度(MIC)和最低杀菌浓度(MBC)评估用 SLNs 和 NLCs 包封的利福平和美洛昔康对铜绿假单胞菌 PAO1 的抗菌活性。结果显示与 NLC 相比,SLN 制剂的 MIC 和最低杀菌浓度剂量较低。此外,我们的研究结果表明,两种纳米制剂都能 100% 地抑制铜绿假单胞菌 PAO1 的生物膜形成。结论所有这些研究结果表明,用 SLNs 封装的美洛昔康和利福平可能是对铜绿假单胞菌最有效的制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Applying the lessons learned from the COVID-19 pandemic to the next generation of nanocarrier-based vaccines. The potential of ceramic nanomaterials in preventive dentistry. Pluronic F127/lecithin PLGA nanoparticles as carriers of monocyte-targeted jakinibs: a potential therapeutic platform. Hispolon-loaded lipid nanocapsules for the management of hepatocellular carcinoma: comparative study with solid lipid nanoparticles and suspension. Nanoformulations of amphotericin B to resolve challenges in antifungal therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1